Logo

Sense Biodetection: John Bishop

Apr 21, 2020

Sense Biodetection appointed John Bishop as a non-executive director.

Bishop, Cepheid's CEO from 2002 until its acquisition by Danaher in 2016, will play a pivotal strategic role at Sense as the company rapidly scales up production and distribution of its first products, including its COVID-19 test, Veros SARS-CoV-2.

At Cepheid, Bishop was instrumental in accelerating the firm's growth as a molecular diagnostics company. He oversaw the successful launch and commercialization of its GeneXpert and GeneXpert Xpress systems.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.